Cargando…
Radiotherapy combined with immune checkpoint inhibitors in locally advanced/metastatic esophageal squamous cell carcinoma: clinical trials, efficacy and future directions
Esophageal squamous cell carcinoma (ESCC) is a common malignancy worldwide and often diagnosed at advanced stages with poor prognosis. Combination of radiotherapy and immunotherapy seems to be a promising approach for treating ESCC. This comprehensive review article summarizes the current state of c...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10261849/ https://www.ncbi.nlm.nih.gov/pubmed/37325652 http://dx.doi.org/10.3389/fimmu.2023.1177085 |
_version_ | 1785057957570936832 |
---|---|
author | Jiang, Mengjie Hu, Yujie Lin, Gang Chen, Chao Li, Huafeng |
author_facet | Jiang, Mengjie Hu, Yujie Lin, Gang Chen, Chao Li, Huafeng |
author_sort | Jiang, Mengjie |
collection | PubMed |
description | Esophageal squamous cell carcinoma (ESCC) is a common malignancy worldwide and often diagnosed at advanced stages with poor prognosis. Combination of radiotherapy and immunotherapy seems to be a promising approach for treating ESCC. This comprehensive review article summarizes the current state of combination of radiotherapy and immunotherapy in locally advanced/metastatic ESCC, delineates the clinical trials that merit attention, and outlines unresolved issues and future research directions in this field. The clinical trial findings suggest that radio-immunotherapy combination may improve tumor response and overall survival with manageable side effects, highlighting the importance of patient selection and the necessity for further research to optimize treatment strategies. Issues such as irradiation dosage, fractionation regimen, irradiation site and technique of radiotherapy, as well as the timing, sequence and duration of combination therapy will all affect treatment outcomes, justifying further in-depth investigation. |
format | Online Article Text |
id | pubmed-10261849 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-102618492023-06-15 Radiotherapy combined with immune checkpoint inhibitors in locally advanced/metastatic esophageal squamous cell carcinoma: clinical trials, efficacy and future directions Jiang, Mengjie Hu, Yujie Lin, Gang Chen, Chao Li, Huafeng Front Immunol Immunology Esophageal squamous cell carcinoma (ESCC) is a common malignancy worldwide and often diagnosed at advanced stages with poor prognosis. Combination of radiotherapy and immunotherapy seems to be a promising approach for treating ESCC. This comprehensive review article summarizes the current state of combination of radiotherapy and immunotherapy in locally advanced/metastatic ESCC, delineates the clinical trials that merit attention, and outlines unresolved issues and future research directions in this field. The clinical trial findings suggest that radio-immunotherapy combination may improve tumor response and overall survival with manageable side effects, highlighting the importance of patient selection and the necessity for further research to optimize treatment strategies. Issues such as irradiation dosage, fractionation regimen, irradiation site and technique of radiotherapy, as well as the timing, sequence and duration of combination therapy will all affect treatment outcomes, justifying further in-depth investigation. Frontiers Media S.A. 2023-05-30 /pmc/articles/PMC10261849/ /pubmed/37325652 http://dx.doi.org/10.3389/fimmu.2023.1177085 Text en Copyright © 2023 Jiang, Hu, Lin, Chen and Li https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Jiang, Mengjie Hu, Yujie Lin, Gang Chen, Chao Li, Huafeng Radiotherapy combined with immune checkpoint inhibitors in locally advanced/metastatic esophageal squamous cell carcinoma: clinical trials, efficacy and future directions |
title | Radiotherapy combined with immune checkpoint inhibitors in locally advanced/metastatic esophageal squamous cell carcinoma: clinical trials, efficacy and future directions |
title_full | Radiotherapy combined with immune checkpoint inhibitors in locally advanced/metastatic esophageal squamous cell carcinoma: clinical trials, efficacy and future directions |
title_fullStr | Radiotherapy combined with immune checkpoint inhibitors in locally advanced/metastatic esophageal squamous cell carcinoma: clinical trials, efficacy and future directions |
title_full_unstemmed | Radiotherapy combined with immune checkpoint inhibitors in locally advanced/metastatic esophageal squamous cell carcinoma: clinical trials, efficacy and future directions |
title_short | Radiotherapy combined with immune checkpoint inhibitors in locally advanced/metastatic esophageal squamous cell carcinoma: clinical trials, efficacy and future directions |
title_sort | radiotherapy combined with immune checkpoint inhibitors in locally advanced/metastatic esophageal squamous cell carcinoma: clinical trials, efficacy and future directions |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10261849/ https://www.ncbi.nlm.nih.gov/pubmed/37325652 http://dx.doi.org/10.3389/fimmu.2023.1177085 |
work_keys_str_mv | AT jiangmengjie radiotherapycombinedwithimmunecheckpointinhibitorsinlocallyadvancedmetastaticesophagealsquamouscellcarcinomaclinicaltrialsefficacyandfuturedirections AT huyujie radiotherapycombinedwithimmunecheckpointinhibitorsinlocallyadvancedmetastaticesophagealsquamouscellcarcinomaclinicaltrialsefficacyandfuturedirections AT lingang radiotherapycombinedwithimmunecheckpointinhibitorsinlocallyadvancedmetastaticesophagealsquamouscellcarcinomaclinicaltrialsefficacyandfuturedirections AT chenchao radiotherapycombinedwithimmunecheckpointinhibitorsinlocallyadvancedmetastaticesophagealsquamouscellcarcinomaclinicaltrialsefficacyandfuturedirections AT lihuafeng radiotherapycombinedwithimmunecheckpointinhibitorsinlocallyadvancedmetastaticesophagealsquamouscellcarcinomaclinicaltrialsefficacyandfuturedirections |